In contradistinction to chronic critical limb ischemia, the peripheral arterial disease patient with intermittent claudication is at relatively low risk for limb loss. As a result, initial claudication management should employ non-interventional therapies rather than immediate catheter-based or surgical revascularization. Although exercise therapy is the most ef cacious conservative treatment for claudication, supervised exercise programs are not widely available at present. Consequently, a pharmacologic agent can be utilized to lessen the symptoms and improve the function of the claudicant. This manuscript provides a comprehensive review of the various pharmacotherapies that have been investigated for improving walking distance in the setting of intermittent claudication. Cilostazol, a phosphodiesterase III inhibitor, appears to provide the greatest bene t, signi cantly improving not only walking distance but quality of life as well. Early trials indicate that propionyl-l-carnitine, oral prostaglandins, l-arginine, and therapeutic angiogenesis may eventually yield signi cant bene t in lessening the symptoms of intermittent claudication.
Introduction
Although peripheral arterial disease (PAD) can deteriorate and manifest ischemic rest pain, painful ulcerations, and/or gangrene, the majority of symptomatic patients suffer from intermittent claudication. When followed over time, roughly 75% of claudicants will remain clinically stable or even improve. 1 ,2 Only a minority deteriorate and require revascularization or limb amputation. 3 ,4 Because of the relatively stable functional prognosis of the PAD patient with claudication, initial therapy is ideally conservative and supportive and not invasive. Although risk factor modi cation and antiplatelet therapy are unequivocally warranted for reducing the considerable cardiovascular risk of the claudicant, such measures fail to improve walking performance. Exercise rehabilitation is a very pro cient method for treating intermittent claudication; however, its effectiveness can be limited by a lack of patient motivation in addition to a shortage of exercise program availability and de cient reimbursement. 5 As a result, pharmacotherapy can be added in an attempt to ameliorate the symptoms of claudication and improve quality of life. The following is a review of pharmaceutical agents that have demonstrable or possible bene t as well as trivial or no bene t in reducing the symptoms of intermittent claudication. fylline is a methylxanthine derivative with numerous hemorheologic properties. Pentoxifylline is traditionally thought to reduce blood viscosity, diminish platelet aggregation, lower plasma brinogen, and improve the deformability of red blood cells. However, these purported effects may no longer be valid since a recent investigation revealed no signi cant difference in whole blood viscosity, erythrocyte deformability, or brinogen levels in patients receiving pentoxifylline over a 24-week period of time. 6 Pentoxifylline's mechanism(s) of action may be white blood cellmediated since other articles have documented subsequent changes in the function, 7 adhesion, 8 and cytoskeleton 9 of the leukocyte.
Although large numbers of studies have investigated pentoxifylline for treating intermittent claudication, only a minority of these have been randomized, placebo-controlled, double-blinded trials. In 1982, Porter et al conducted one of the initial randomized pentoxifylline trials. 1 0 In this investigation, pentoxifylline improved the pain-free walking distance (PFWD) and maximal walking distance (MWD) by 22% and 12% respectively compared to placebo; however, these differences were not statistically signi cant over a 24-week period. Lindegarde et al randomized 150 claudicants to pentoxifylline or placebo over 24 weeks. 1 1 Although pentoxifylline increased the MWD by 21%, this was not statistically signi cant. A Canadian meta-analysis of 11 randomized, controlled trials published between 1974 and 1996 documented that pentoxifylline signi cantly increased the mean MWD by 48.4 m. 1 2 However, since the majority of patients receiving placebo also had considerable improvement in walking distance, the authors questioned whether the modest improvement with pentoxifylline was even clinically signi cant. The recently published Claudication Study Group is the largest randomized, prospective trial to date comparing pentoxifylline (n = 232) to placebo (n = 239). 1 3 In this study, the improvement in PFWD and MWD with pentoxifylline was no different than that of placebo (p = 0.82). One study actually documented a 21% decrease in PFWD in patients treated with pentoxifylline 1 4 (Table 1 ). In their critical analysis of seven placebo-controlled pentoxifylline trials, Cameron et al observed that pentoxifylline ef cacy and trial sample size were inversely related, thus suggesting an inherent publication bias. 2 8 Notably, the majority of pentoxifylline trials failed to assess for functional improvement through the use of the Medical Outcomes Study Short Form 36 (SF-36) or the Walking Impairment Questionnaire (WIQ). In the one study that did employ patient-based questionnaires, pentoxifylline was no different than placebo in improving subjective outcomes. 1 3 The majority of side effects involve the gastrointestinal and central nervous system. The most common gastrointestinal complaints are nausea, dyspepsia, and vomiting. Usual central nervous system complaints are dizziness and cephalgia.
In summary, though pentoxifylline may provide modest improvement in walking distance in some patients, any bene t appears erratic and probably clinically insigni cant. Thus, physicians have become increasingly suspect about the ability of pentoxifylline to improve intermittent claudication. 
Cilostazol
Cilostazol was approved by the FDA in 1999 for reducing the symptoms of intermittent claudication. A 2-quinolinone compound, the medication suppresses cyclic adenosine monophosphate (cAMP) degradation via phosphodiesterase III inhibition. Consequently, the level of cAMP in platelets and blood vessels is increased, leading to inhibition of platelet aggregation and to vasodilation, respectively. 2 9 -3 1 In addition to platelet inhibition and vasodilation, cilostazol also has antithrombotic properties and inhibits vascular smooth muscle cell proliferation in vitro. Despite these multiple pharmacologic effects, the precise mechanism(s) of action that improves walking performance is unclear.
The medication also has salutary lipid modulating effects. In one placebo-controlled study, subjects who received cilostazol (100 mg bid) for 12 weeks experienced a 15% decrease in triglyceride levels and a 10% increase in high-density lipoprotein (HDL) cholesterol. 3 2 In four US Phase III multicenter, randomized, blinded trials, over 1500 claudicants were administered cilostazol over a 12-24 week period. Across these studies, the range of improvement in MWD in patients treated with cilostazol 100 mg twice daily compared with placebo was 32-73%. 1 Week Figure 1 Geometric mean per cent change in MWD over time in three treatment groups: cilostazol 100 mg, cilostazol 50 mg, and placebo. 1 7 Cilostazol exhibits dose-responsive bene t. Upon completion of a 24-week study, subjects who received cilostazol 100 mg twice daily improved their MWD by 51% (p , 0.001 vs placebo) whereas a 50 mg twice-daily dose increased the MWD by only 38% (p , 0.001 vs placebo). 1 7 Alternatively, the MWD increased by 129.1 m and 67.3 m compared with baseline in the 100 mg and 50 mg twicedaily groups respectively. The placebo group increased their MWD by an insigni cant 26.8 m ( Figure 1 ).
The ef cacy of cilostazol was directly compared with pentoxifylline in the largest randomized, blinded, prospective, pharmacologic claudication trial to date. 1 3 In this study, 698 patients with moderate to severe claudication were randomized to one of three treatment arms (cilostazol 100 mg orally bid, pentoxifylline 400 mg orally tid, or placebo). Subsequently, the MWD was determined via constant speed, variable grade treadmill testing at baseline and at 4, 8, 12, 16, 20, and 24 weeks. At 24 weeks, the MWD increased by a mean of 107 m (mean per cent increase = 54%) in patients receiving cilostazol whereas the MWD increased by only 64 m (mean per cent increase = 30%) and 65 m (mean per cent increase = 34%) in patients treated with pentoxifylline (p = 0.0002) and placebo (p = 0.0005), respectively ( Figure 2 ). The improvement in walking dis- tance was noted in the cilostazol subgroup as early as 4 weeks (p = 0.02). It is worth re-emphasizing that the improvement in the MWD between the pentoxifylline and placebo groups was essentially equivalent (p = 0.82). Unique to cilostazol is its ability to favorably in uence subjective, functional parameters. For instance, in Beebe's multicenter claudication trial, subjects were randomized to receive cilostazol 100 mg, cilostazol 50 mg, or placebo bid. 1 7 Subsequently, patients were queried via functional status forms (SF-36, Walking Impairment Questionnaire (WIQ), and Claudication Outcome Measures (COM)) and a global therapeutic assessment after 24 weeks of therapy. The patients who received cilostazol (100 mg and 50 mg groups) experienced statistically signi cant improvement versus placebo in the SF-36 scales such as physical function and bodily pain. Similarly, the WIQ documented signi cant increases in the walking distance and walking speed with the use of both cilostazol doses (Table 2 ). Finally, a Global Therapeutic Assessment at 24 weeks revealed that both patients and investigators rated their results as signi cantly 'better' or 'much better' with cilostazol than placebo.
Several studies have objectively documented increases in post-treatment arterial perfusion with cilostazol. In an investigation of nine patients with PAD, cilostazol administered for 2 weeks increased the mean ankle blood ow by 16.2% (p , 0.05 vs baseline). 3 3 Money et al documented a statistically signi cant increase in the ankle-brachial index (ABI) when cilostazol was compared with placebo (0.64 to 0.70 in the cilostazol group vs 0.68 to 0.69 in the placebo group, p , 0.0125). 1 6 Most recently, Mohler et al documented an increase in the mean resting ABI by 0.03 (p = 0.0039) and 0.04 (p = 0.0001) in a cohort of patients treated for 24 weeks with cilostazol 100 mg and 50 mg twice daily, respectively, versus placebo. 3 4 However, the increased post-therapeutic ABI may not be functionally relevant. In accordance with established revascularization guidelines, an increase in the ABI of less than 0.1 is probably clinically insigni cant. 3 5 According to the cilostazol safety database, the most common side effect of cilostazol is cephalgia, occurring in 26% and 33% of patients receiving 50 mg and 100 mg twice daily, respectively. 3 6 However, headache that necessitates medication discontinuance occurs in roughly 1% and 4% of patients taking 50 mg and 100 mg twice daily, respectively (versus 0.3% of patients administered placebo). Less common side effects include diarrhea, dizziness, palpitations, and peripheral edema ( Table 3) .
Although other phosphodiesterase III inhibitors (e.g. milrinone) have been associated with an increased risk of sudden cardiac death in congestive heart failure patients, cilostazol has never been de nitively linked with untoward cardiovascular morbidity and mortality. In reviewing the cilostazol safety database, myocardial infarction occurred in 1.0%, 0.8%, and 1.1% of cilostazol-treated, placebotreated, and pentoxifylline-treated patients, respectively. Nevertheless, due to a potential class effect of phosphodiesterase inhibitors, cilostazol use remains contraindicated in patients with a history of prior or current congestive heart failure.
Bu omedil
Bu omedil is an anti-adrenergic medication that inhibits both alpha 1 and 2 receptors, thus producing a vasodilatory effect. In addition, bu omedil improves erythrocyte deformability, reduces the oxygen requirements of muscle cells, and inhibits platelet aggregation. Two remote trials with relatively small numbers of subjects demonstrated a signi cant improvement in absolute claudication distance (ACD) in patients receiving bu omedil versus placebo. However, the medication is not available in the USA. 3 7 ,3 8 Levocarnitine and propionyl-l-carnitine Acylcarnitines are intermediates of oxidative metabolism that accumulate in the ischemic leg muscles of the claudicant. The amount of muscle acylcarnitine appears inversely correlated with exercise performance. 3 9 The administration of the metabolic enhancing agents levocarnitine and propionyl-l-carnitine appears to enhance ischemic muscle metabolism and subsequently augment walking capacity. Of these two medications, propionyl-l-carnitine is more effective. 2 1 When compared with placebo, propionyl-l-carnitine signi cantly improved the MWD by 27% to 41% in two multicenter claudication trials. 2 2 ,4 0 In a recent doubleblind, randomized, placebo-controlled trial of 155 patients with claudication, propionyl-l-carnitine (2 g/day orally for 24 weeks) was superior to placebo not only in objectively improving peak walking time (p , 0.001) but also in improving subjective scores on the WIQ and the SF-36. 4 1 The medication was well tolerated with a discontinuation rate similar to placebo. Interestingly, propionyl-l-carnitine Vascular Medicine 2002; 7: 301-309 appears to preferentially bene t claudicants with severe functional impairment. For example, Brevetti et al showed that propionyl-l-carnitine was ef cacious when administered to patients with an MWD of #250 m whereas patients with limited function impairment (MWD . 250 m) did not respond to the medication. 4 0 Although the trial outcomes with propionyl-l-carnitine are encouraging, the medication has not been approved for use in the USA.
Naftidrofuryl
Naftidrofuryl is a 5-HT 2 (serotonin) antagonist with vasodilatory 4 2 and possibly hemorrheologic effects. It may also promote aerobic glycolysis and ATP supplementation in skeletal muscle. 4 3 Placebo-controlled trials of naftidrofuryl have produced con icting results. In a meta-analysis, four level I trials documented a signi cant increase in PFWD (common difference of the means = 58.6 m) with naftidrofuryl versus placebo. 4 4 However, two other studies revealed no difference between naftidrofuryl and placebo in improving MWD. 1 8 ,1 9 Side effects include dyspepsia, nausea, and rashes. Since heart block can be provoked by high doses of naftidrofuryl, it is contraindicated in patients with second or third degree atrioventricular block. Although utilized in Europe for over 20 years, naftidrofuryl is not available in the USA for treating claudication. 
l-Arginine
The amino acid l-arginine facilitates nitric oxide production and endothelial-dependent vasodilatation in peripheral arterial disease patients. Boger et al were the rst investigators to illustrate that l-arginine restores vascular nitric oxide and improves the symptoms of intermittent claudication. 4 5 In this randomized, controlled study, patients administered l-arginine (two daily intravenous infusions of 8 g for 3 weeks) increased their PFWD by 230 6 63% and their MWD by 155 6 48% (each p , 0.05). The placebo group had no signi cant improvement in their walking parameters. With the exception of an isolated mild allergic skin rash, intravenous l-arginine was well tolerated. A subsequent small, double-blind, placebo-controlled study (n = 41) analyzed the effectiveness of an l-arginineenriched food bar. 4 6 Subjects who consumed two food bars/day for a 2-week period signi cantly improved their PFWD by 66% (p , 0.05 vs baseline data) and MWD by 23% (p = 0.05 vs baseline data). Furthermore, the SF-36 health questionnaire documented improvements in general function, and emotional and social health in patients who received two bars/day. No improvement was identi ed in the patients randomized to either one food bar/day or placebo. These bene ts were maintained after 8 additional weeks of open label use. The only minor side effect of the l-arginine food bar was xerostomia (n = 2).
Prostaglandins
Although the majority of prostaglandin trials involve patients with chronic critical limb ischemia, several studies have evaluated prostaglandins in the setting of intermittent claudication. In a randomized controlled study, patients who received an intravenous prostaglandin E 1 prodrug for 5 days/week over a 4-week period signi cantly increased both their PFWD and MWD compared to placebo. 2 3 Moreover, improvements were noted in quality of life parameters.
Since daily parenteral prostaglandin administration is somewhat impractical, several recent trials have investigated oral prostaglandins for ameliorating claudication. For example, 422 claudicants were randomized to either beraprost sodium (40 mg tid, n = 209) or placebo (n = 213) in a double-blind fashion for 6 months. 2 6 The PFWD increased by 81.5% and 52.5% respectively in the beraprost and placebo groups (p = 0.001) and the MWD by 60.1% and 35.0%, respectively (p = 0.004). This trial also documented a salutary effect of beraprost sodium on quality of life. Side effects of prostaglandins include headache, ushing, and gastrointestinal intolerance.
The preliminary results of prostaglandin use for intermittent claudication are encouraging but further supportive investigation is needed.
Ginkgo biloba
Extracts from the leaves of Ginkgo biloba have been used for treating intermittent claudication. The majority of investigations have utilized EGb 761, an extract standardized to 24% ginkgo avone glycosides. The mechanisms of action(s) remain incompletely de ned but may involve metabolic changes, vasoregulatory in uences, and inhibition of free radical-induced membrane damage. 4 7 A recent meta-analysis examined eight randomized, placebocontrolled, double-blind trials and established that the PFWD was signi cantly greater (weighted mean difference: 34 m, 95% con dence interval: 26 to 43 m) for patients taking Ginkgo biloba compared with placebo. 4 8 The usual therapeutic dose of Gingko biloba is 120 mg per day; however, in a randomized, double-blind comparison trial, patients treated with the standard dose (120 mg/day) and a higher dose (240 mg/day) increased their PFWD by a mean of 60.6 m and 107.0 m, respectively (p = 0.0253). 4 9 Ginkgo biloba is inexpensive and well tolerated. In conclusion, Ginkgo biloba ef cacy appears greater than placebo in treating intermittent claudication but the improvement is modest and may not be clinically relevant.
Therapeutic angiogenesis
In therapeutic angiogenesis, mitogens such as vascular endothelial growth factor (VEGF) and basic broblast growth factor (b-FGF or FGF-2) are administered in order to stimulate collateral vessel proliferation and thereby improve perfusion in the ischemic limb. In a small Phase I trial of patients with intermittent claudication, femoral artery infusions of recombinant b-FGF signi cantly improved calf blood ow as documented by strain gauge plethysmography. 5 0 Speci cally, nine patients treated with b-FGF achieved a 66 6 26% increase in calf perfusion at 1 month and a further increase of 153 6 51% at 6 months (p , 0.05 at 1 and 6 months). In another Phase I multicenter investigation, 18 patients with intermittent claudication and 15 patients with rest pain were randomized to placebo or intramuscular CI-1023, an adenoviral vector encoding the 121 isoform of VEGF. 5 1 Patients receiving CI-1023 experienced a trend in improvement of the ACD. Subsequent revascularization and/or amputations did not differ between the two groups. Serious adverse sequelae (related and unrelated) occurred in 15/28 (53.6%) of the subjects receiving CI-1023 and in 4/5 (80%) of those receiving placebo. The most common CI-1023-related side effects included injection site edema, rash, and hemorrhage. In a placebo-controlled, double-blind, Phase II study, 45 patients with chronic lower extremity ischemia were randomized to placebo (n = 15), VEGF-adenovirus (n = 15), or VEGF-plasmid/liposome (n = 15) after percutaneous transluminal angioplasty. 5 2 Three-month follow-up digital subtraction angiography displayed signi cantly improved vascularity in the two groups that received VEGF. Moreover, the Rutherford class and ABIs were signi cantly improved in the VEGF groups. Finally, the Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) study is the largest Phase II randomized, blinded, placebo-controlled study investigating the ef cacy of therapeutic angiogenesis for PAD in man. 5 3 In the TRAFFIC study, 190 patients with moderate to severe claudication were randomized to obtain broblast growth factor-2 (FGF-2) or placebo. All the patients in the treatment arms received a single dose of 30 mg/kg of bilateral intra-arterial FGF-2 on day one. A portion of the treated patients received a second dose of FGF-2 on day 30. The primary endpoint measured was the change in pain-free walking time (PWT) at 90 days. Subjects receiving placebo (n = 63), single-dose (n = 66), and double-dose (n = 61) FGF-2 increased their PWT by 0.60 (14%) min, 1.77 (34%) min, and 1.54 (20%) min, respectively. The increase in the PWT with single-dose FGF-2 was statistically superior to placebo (p = 0.026); however, the Vascular Medicine 2002; 7: 301-309 improvement with double-dose FGF-2 was surprisingly statistically insigni cant (p = 0.45).
Unacceptable adverse effects may possibly negate any potential bene t of therapeutic angiogenesis. A recently published study of intravenous b-FGF for intermittent claudication was prematurely terminated when ve of the 16 patients that received the medication (2 mg/kg per week intravenously for 6 weeks) developed proteinuria. 5 4 In four of these ve patients, the degree of proteinuria exceeded 1000 mg/24 h. Although the sample size of this investigation was too minute for statistical examination, nausea, diarrhea, and anorexia developed in 19%, 13%, and 6% of the patients receiving intravenous b-FGF. None of the placebo-treated subjects experienced gastrointestinal side effects.
Pharmacotherapy with trivial or no bene t

Chelation therapy
Although chelation has been employed as the modality to treat PAD, critical corroborative data to support its use is lacking. When four randomized, placebo-controlled, double-blind trials of intravenous disodium EDTA for PAD were reviewed, the medication failed to provide signi cant bene t in relieving the symptoms of intermittent claudication. 5 5 Moreover, clinical signs of potentially dangerous hypocalcemia have been reported. In conclusion, the TASC working group stated, 'There is no scienti c basis for the use of chelation therapy in the treatment of peripheral arterial disease.' 5 6 Anticoagulation A recent Cochrane database review concluded that unfractionated heparin, low molecular weight heparin, and oral anticoagulants are not effective in reducing the symptoms of intermittent claudication. 5 7 Furthermore, major and minor bleeding episodes were more frequent in the cohort that received oral anticoagulants compared to placebo.
Verapamil
Although an unusually designed isolated study of 44 patients documented a mean increase in the MWD by 49% when verapamil was compared with placebo, the treatment and follow-up period was only 2 weeks. 5 8 Based on this small and very brief trial, verapamil cannot be enthusiastically endorsed for improving the symptoms of intermittent claudication.
Vitamin E
The Cochrane Review examined ve previous randomized controlled trials comparing vitamin E with placebo for the treatment of intermittent claudication. 5 9 The reviewers concluded that although vitamin E is inexpensive, relatively safe, and may have some favorable properties, there is simply insuf cient data at present to recommend its use as therapy for intermittent claudication.
Antiplatelet medications
Although antiplatelet therapy reduces the risk of cardiovascular events in the claudicant, there is a lack of convinc-ing evidence that medications such as aspirin or dipyridamole improve walking ability. Two randomized, controlled, claudication trials suggested that the thienopyridine derivative ticlopidine modestly improved walking distance yet both studies had potential limitations. 2 7 ,6 0 For instance, one of the trials could have overestimated ticlopidine's ef cacy since treadmill testing was performed without inclination. 2 7 In a recent meta-analysis of randomized claudication trials, the authors noted that the long-term walking bene ts of ticlopidine were no different than placebo. 6 1 Due to potentially deleterious hematologic side effects (e.g. agranulocytosis, thrombocytopenia, and pancytopenia) combined with a paucity of de nitive supportive data on improving walking performance, ticlopidine cannot be recommended as an ideal pharmacologic agent for claudication therapy.
Clopidogrel is a thienopyridine medication with antiplatelet properties. Though the CAPRIE trial demonstrated clopidogrel's superiority to aspirin (acetylsalicyclic acid) in reducing ischemic vascular events in 6452 PAD patients (relative risk reduction 24%), there is no medical evidence to date that clopidogrel relieves the symptoms of intermittent claudication. 6 2 
Ketanserin
Ketanserin inhibits serotonin-mediated vasoconstriction and platelet aggregation. It also exhibits alpha-1 adrenergic antagonism. Although an initial trial suggested that ketanserin signi cantly improved walking performance, 6 3 multiple subsequent studies documented no improvement 6 4 or even worsening 6 5 of claudication when ketanserin was administered. Consequently, ketanserin cannot be recommended for the treatment of intermittent claudication.
Vasodilators
Although provoking arterial vasodilation should intuitively increase limb perfusion, medications with vasodilatory properties have failed to improve walking distance in randomized, controlled trials of claudication patients. For example, in a small, randomized, controlled trial, slow release nifedipine (20 mg twice daily) did not improve the PFWD or MWD of patients with intermittent claudication. 6 6 Various potential explanations for a lack of vasodilator ef cacy exist. For example, since vasodilators decrease systemic pressure, the corresponding reduction in perfusion pressure may be responsible. Alternatively, the peripheral arteries supplying ischemic muscles are already dilated and adding a vasodilator induces a 'steal' of blood ow to responsive arteries supplying non-ischemic muscle. Last of all, atheromatous peripheral arteries are sclerotic and therefore may be unresponsive to vasodilators, thus leading to a 'steal' phenomenon within normal arteries and muscles. In conclusion, multiple trials have failed to document vasodilator ef cacy in treating claudication. 6 7 
Conclusion
Although the predominant objective of claudication therapy is cardiovascular risk factor modi cation, important secondary objectives include improving walking distance and upgrading quality of life. When a claudicant cannot bene t from exercise rehabilitation, then a trial of pharmacologic Vascular Medicine 2002; 7: 301-309 treatment is warranted if no contraindications exist. In reviewing the aforementioned data, the phosphodiesterase III inhibitor cilostazol emerges as the most ef cacious medication at present for improving claudication. Not only does cilostazol signi cantly increase PFWD and MWD when compared with placebo, but it also improves quality of life. Preliminary data also suggests that propionyl-l-carnitine, oral prostaglandins, l-arginine, and therapeutic angiogenesis may ultimately prove useful in treating claudication as well.
